Lexington Receives Approval to Commence Clinical Study

January 24, 2018

Company prepares for volunteer enrollment

VANCOUVER, British Columbia, Jan. 24, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce its recent application for Institutional Review Board (“IRB”) approval of its pilot clinical study at Diablo Clinical Research has been approved.

As previously noted, approval by an IRB, or ethics board, is necessary before human research can begin. The IRB has reviewed Lexington’s submission for both medical safety and protection of the patients involved in the study and has subsequently advised of its approval as submitted. With approval in-hand, the Company has engaged a clinical investigative team and research site in preparation for the process of volunteer enrollment.

Lexington’s President Eric Willis comments, “The rapid approval of our clinical study submission speaks volumes to our team’s diligent attention to the design of the product and required documentation, as well as the format of the proposed study itself.  We are planning to immediately move ahead into the investigative phase of our studies aimed at achieving eventual FDA clearance for our HeartSentry device. This means we are proceeding rapidly toward our strategic goals. Our thorough planning means we are also in great shape to act on the approval right away. We are very happy to begin this most critical phase of our development to-date and look forward to the work ahead.”

To find out more about Lexington Biosciences, interested readers are invited to visit our website and view our video featuring principal HeartSentry inventor Dr. Jonathan Maltz, Ph.D., which provides an excellent overview of our business proposition and opportunity ahead. Please also follow us on FacebookTwitter and LinkedIn.

About Lexington Biosciences, Inc. (CSE: LNB / OTCQB: LXGTF)
Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and monitor cardiovascular health by assessing the function of a person’s vascular endothelium – the vital innermost lining of a person’s cardiovascular system.  Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician.  The HeartSentry core technology was developed at the University of California Berkeley over a fifteen-year R&D period involving many research studies and product iterations resulting in a portfolio of multiple pending and issued patents licensed to the company. Our aim is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.  Lexington is engaged with the US FDA and other regulatory agencies on the required product approvals for the HeartSentry. For more information about the company please visit: https://lexingtonbiosciences.com/.

On Behalf of the Board,

“Eric Willis”

Eric Willis
CEO & Director

CAUTIONARY DISCLAIMER STATEMENT:  The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to the completion of the listing of the Company’s shares on the Canadian Securities Exchange and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

CONTACT:
Lexington Biosciences, Inc.
+1 (800) 320-2640
[email protected]
www.lexingtonbiosciences.com

Renmark Financial Communications Inc.
Laura Welsh: [email protected]
Tel: (416) 644-2020 or (514) 939-3989
www.renmarkfinancial.com


Historical Press Releases
This website contains historical and archived press releases for Lexington BioSciences Inc.. The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, Lexington BioSciences Inc.. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

Archives

Categories

Newsletter Updates

If you haven’t already done so, signup here to receive future editions and the latest company news direct to your inbox.

Latest News